Abstract
e22215Background: The introduction of everolimus (E), an mTOR inhibitor, was shown to improve clinical benefit in endocrine and trastuzumab resistant advanced breast cancer by mediating via the PI3...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
